Keytruda and Sitagliptin phosphate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Keytruda (pembrolizumab) and Sitagliptin phosphate (sitagliptin phosphate). Common drug interactions include thyroiditis among females and adrenal disorder among males.

The phase IV clinical study analyzes what interactions people have when they take Keytruda and Sitagliptin phosphate. It is created by eHealthMe based on reports of 19 people who take the same drugs from the FDA, and is updated regularly.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.

What is Sitagliptin phosphate?

Sitagliptin phosphate has active ingredients of sitagliptin phosphate. eHealthMe is studying from 3,787 Sitagliptin phosphate users. Check the latest studies of Sitagliptin phosphate.

On Aug, 01, 2026

19 people who take Keytruda and Sitagliptin phosphate together, and have interactions are studied.

Keytruda and Sitagliptin phosphate drug interactions.

What are the common drug interactions of Keytruda and Sitagliptin Phosphate, by gender? *:

female:

Thyroiditis (inflammation of thyroid gland)
Thyrotoxic crisis (a life threatening condition due to excess secretion of thyroid hormone)
Blood thyroid stimulating hormone increased
Suicidal ideation
Diarrhoea
Encephalopathy (functioning of the brain is affected by some agent or condition)
Femoral neck fracture (neck of femur bone fracture)
Infection
Toxic epidermal necrolysis (a rare, life-threatening skin condition that is usually caused by a reaction to drugs causes wide spread skin destruction)
Malignant neoplasm progression (cancer tumour came back)

male:

Adrenal disorder
Delirium (wild excitement)
Muscular weakness (muscle weakness)
Nausea (feeling of having an urge to vomit)
Pyrexia (fever)
Alanine aminotransferase increased
Aspartate aminotransferase increased
Drug-induced liver injury (diseases of the liver that are caused by physician-prescribed medications)
Hepatic enzyme increased
Interstitial lung disease

What are the common drug interactions of Keytruda and Sitagliptin Phosphate, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Thyroiditis (inflammation of thyroid gland)
Thyrotoxic crisis (a life threatening condition due to excess secretion of thyroid hormone)
Blood thyroid stimulating hormone increased
Suicidal ideation
Malignant neoplasm progression (cancer tumour came back)

50-59:

n/a

60+:

Adrenal disorder
Delirium (wild excitement)
Hepatocellular carcinoma (liver cancer)
Hypoaesthesia (reduced sense of touch or sensation)
Infection
Infusion related reaction
Muscular weakness (muscle weakness)
Nausea (feeling of having an urge to vomit)
Pyrexia (fever)
Toxic epidermal necrolysis (a rare, life-threatening skin condition that is usually caused by a reaction to drugs causes wide spread skin destruction)

What are the existing conditions these people have? *

Endometrial Cancer: 5 people, 26.32%
Diabetes: 3 people, 15.79%
Therapeutic Embolisation: 3 people, 15.79%
Interstitial Lung Disease: 2 people, 10.53%
Lung Adenocarcinoma Stage Iv (the cancer has spread to other organs of the body, such as the other lung, brain, or liver): 2 people, 10.53%
Fever: 2 people, 10.53%
Infusion Related Reaction: 2 people, 10.53%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 2 people, 10.53%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 10.53%
Nausea (feeling of having an urge to vomit): 2 people, 10.53%

* Approximation only. Some reports may have incomplete information.

Do you take Keytruda and Sitagliptin phosphate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously